Rusnak M G, Drake T A, Hackbarth C J, Sande M A
J Infect Dis. 1984 Jun;149(6):980-5. doi: 10.1093/infdis/149.6.980.
Studies of therapy for experimental pneumonia due to Pseudomonas aeruginosa have failed to document beta-lactam-aminoglycoside synergy for most antibiotics examined, in contrast to results usually observed with pseudomonas infections at other sites. The neutropenic guinea-pig model of pseudomonas pneumonia was modified to resemble more closely therapy for clinical infections. Animals were treated 16 hr after infection with ticarcillin, azlocillin, ceftazidime, tobramycin, and netilmicin, alone and in combination. As predicted by in vitro synergy testing, in all cases combination drug therapy was more effective than the corresponding drugs given alone (P less than .05), as assessed by quantitative lung culture. Among single-drug regimens, those in which peak antibiotic levels did not exceed the minimal bactericidal concentration for the organism were significantly less effective. Resistance to aminoglycosides did not develop during therapy, and therefore, in this study does not explain the mechanism of synergy observed with beta-lactam antibiotics.
对铜绿假单胞菌所致实验性肺炎的治疗研究未能证明,对于大多数所检测的抗生素而言,β-内酰胺类抗生素与氨基糖苷类抗生素具有协同作用,这与在其他部位的假单胞菌感染中通常观察到的结果相反。对铜绿假单胞菌肺炎的中性粒细胞减少豚鼠模型进行了改良,使其更类似于临床感染的治疗情况。感染16小时后,用替卡西林、阿洛西林、头孢他啶、妥布霉素和奈替米星单独及联合治疗动物。正如体外协同试验所预测的那样,通过定量肺培养评估,在所有情况下联合药物治疗均比相应的单一药物治疗更有效(P<0.05)。在单一药物治疗方案中,抗生素峰值水平未超过该菌最低杀菌浓度的方案效果明显较差。治疗期间未出现对氨基糖苷类抗生素的耐药性,因此,在本研究中这无法解释观察到的β-内酰胺类抗生素协同作用机制。